Latest Us Market News

betr Entertainment Limited posts a 140% turnover increase to $1.42 billion and achieves a positive EBITDA of $7.2 million in FY25, driven by strategic mergers and market exits. The company ups its takeover bid for PointsBet, signaling aggressive consolidation ambitions.

betr Entertainment Limited marked a transformative FY25 with a successful merger, strategic acquisitions, and a sharp reduction in losses, setting the stage for a major takeover bid of PointsBet.

Lynas Rare Earths reports FY25 revenue growth amid profit decline, completes major capital projects, and launches a $750 million equity raise to fund its expansive Towards 2030 strategy.

BetMakers Technology Group has completed a major transformation in FY25, delivering positive adjusted EBITDA and strong operating cash flow while expanding its global footprint with a strategic US acquisition.

BetMakers Technology Group delivered a strong FY25 with a 5.6% half-on-half revenue growth and record profitability, while advancing its technology transformation and signing a strategic acquisition in Nevada.

Micro-X Limited reported a $13.9 million loss for FY2025 as it pivots towards medical imaging, securing a landmark supply agreement with a major US healthcare provider for its Rover Plus mobile X-ray system.

Appen Limited reported a modest 2% revenue increase in H1 FY25, driven by a 67% surge in its China business, while reaffirming full-year guidance amid US market uncertainties.

Appen Limited reported a 9.2% revenue decline to $103.2 million for H1 2025, offset by robust 67% growth in its China business unit. Despite increased net losses, the company maintains a strong cash position and focuses on generative AI expansion and operational efficiency.

Thorney Opportunities Ltd posted a sharp 76% decline in profit after tax for FY2025 yet declared a higher fully franked final dividend and reported growth in net tangible assets per share.

Cyclopharm Limited reported a 26% revenue increase for the half year ended June 2025, driven by rapid US market expansion and strong growth in its Third-Party distribution business. Despite a wider net loss, the company secured a key patent extension and reaffirmed its target to install 250-300 Technegas® systems in the US by late 2026.

Nova Eye Medical has delivered solid FY25 results, meeting sales guidance outside China and achieving six consecutive halves of growth in the US market. The company also improved gross margins and reduced cash burn, setting an optimistic tone for FY26 with breakeven EBITDA guidance.

Nova Eye Medical has reported a record A$29.3 million in FY25 revenue, driven by sustained US growth and operational improvements, setting the stage for breakeven EBITDA in the first half of FY26.